

Contipro Group Holding

Eva Černá

21.9.2009

CONTIPRO GROUP HOLDING

Mother company, servis and administration of holding (technological support, sales, human resources, etc)

Production of final pharmaceutical preparations and APIs

Production of active substances for cosmetics and nutrition

R&D laboratories

HISTORY



1990

First company Contipro based

- nutritional supplements & cosmetics

1991

Development of hyaluronan production by biotechnological way

1992

Hyaluronan cosmetic grade launched

- building of world wide distribution network

1997

CPN company based

- new substances for cosmetics launched
- hyaluronan nutrition grade launched

1998

Development of hyaluronan pharmaceutical quality finalized

Development of final pharma products started

2000

Division of nutritional supplements & cosmetics sold

First final pharm.product Bonharen introduced

2003

First PTC patent application for wound healing MD Hyiodine

2004

Contipro Group holding based

Contipro Group

NOWADAYS

- 153 employees
- sales (2008) – 9,6 mil EUR
- export – 98% of the whole sales
- one of the biggest producers of hyaluronan in the world
  - 30% of the world market
  - 60% of European market
- sales in 36 countries

Contipro Group

RAW MATERIALS

Hyaluronan as a core product

- 30% of worldwide market share and 60% of European market
- various qualities, produced in separated production lines including pharmaceutical grade with DMF & CoS

Besides hyaluronan we cover a **range of active ingredients used in pharmacy and cosmetics of biotechnological (non-animal origin)**

- Schizophyllan
- TanActine
- Carboxymethylglucan

Sterile injectables in vials based on hyaluronan (shortly also in prefilled syringes)

Contipro Group

FINAL PHARMACEUTICAL PRODUCTS

PATENTED WOUND COVERAGE
based on sodium hyaluronate

- Exceptional results with diabetic ulcers, bed sores and large dehiscences after surgery
- Universal and easy application
- No reports of any side effects

VETERINARY DRUGS
for therapy of inflammatory joint reaction
based on sodium hyaluronate

- Excellent viscoelastic properties faciliate easy lubrication of articular surfaces
- Reduces inflammation and cartilage degeneration
- Improves health and functions of articular soft tissues

QUALITY

CPN - raw materials for cosmetic

- top quality in the new state-of-the-art production facilites
- quiding principles of GMP
- ISO 9001: 2000 certified

Contipro C - active pharmaceutical ingredients, drugs and medical devices

- cGMP
- CoS (certificate of suitability to PhEur)
- ISO 9001:2000
- ISO 13485:2003 for medical devices

Contipro Group

RESEARCH & DEVELOPMENT

Research & Development
- key area of activity for the company

- CG laboratories have reputation as one of **the most advanced centres in the field of hyaluronan-related chemistry and biology**.
- Over 30% employees are scientists, researchers and developers.
- Implementation of latest technologies and methods for research and development in the field of fermentation technology, molecular biology, genetics and the physical chemistry of biopolymer solutions

Contipro Group

R&D FOCUS

- tissue engineering
- wound healing
- targeted drug delivery
- dermatology and antiaging



Technological labs

development of new raw materials

(new biotech. ingredients, crosslinked and modified hyaluronans)

Application labs

dermatological, ophtalmological, orthopedics, tissue engineering, drug delivery and wound healing applications

Labs for efficacy data

Testing of efficacy – raw materials and final products

Contipro Group

PUBLICATIONS (since 2005)

Czech Republic

Publications - 4

Patents – 2

Patent application – published - 6

not published - 4

Europe

Patents – 2

Worldwide

Publications - 26

Patents – 1

Patent application - published -3

not published -1

Contipro Group

COOPERATION WITH RESEARCH INSTITUTES



We cooperate closely with number of universities and research institutes in the Czech Republic and abroad.

The total list covers around 20 cooperating centres, to which the holding awards research grants for specific projects.

The results of holding R&D are published in prestigious magazines.

The holding also regulary attends conferences and scientific symposia around the world.

Contipro Group

Medicine – pharmaceutical Cluster Nanomedic



The mission of cluster Nanomedic

- to support R&D in the area of nanomaterials and biotechnology
- to enhance the ability to compete, innovative activities and the export of companies, universities and academic institutions.

Goals of cluster Nanomedic

- To associate SMEs, universities and research institutes focused on the development and production of high-tech products for selected medical applications
- To initiate the foundation and development of new production sites designed for the industrial production of regenerative medicinal products, targeted drug delivery and gene therapy
- Establishment of a new academic field focused on the regenerative medicine, targeted drug delivery, gene therapy and education of future emloyees
- Foundation of a virtual science & technology park focused on the regenerative medicine, targeted drug delivery, gene therapy facilitating the grounding of small enterprises and spin-off companies

nanomedic

Medicine – pharmaceutical Cluster Nanomedic



Scope of Nanomedic Cluster

- Development and production of new medical products
- External wound and burn covers based on biologically active substances prepared using nanotechnology
- Internal wound covers, materials for antiadhesive products and internal temporary plasters based on biopolymers prepared by nanotechnology
- Materials and ready-to-use kits for tissue engineering_Systems for targeted drug delivery based on nanoparticles, liposoms, micelle-like structure etc._Materials and ready-to-use kits for gene therapy
- Development of new technology for the industrial implementation of above-mentioned products
- Development of new analytical methods for the testing and control of above-mentioned products

nanomedic

Medicine – pharmaceutical Cluster Nanomedic



Legal Subjects of Nanomedic

Ampi, spol. s r.o.
B A T I S T s.r.o.
Biohem Diagnostika spol. s r.o.
BLOCK a.s.
CESA, a.s., Pardubice
CPN spol. s r.o.
Contipro Group s.r.o.
Enantis s.r.o.
Generi Biotech s.r.o.
I N O T E X spol. s r.o.
Inova Pro, s.r.o.
Intero, Chmelan a spol., společnost s ručením omezeným
MUDr. Pavel Nožička, CHS Galen
SAFIBRA, s.r.o.
SEDIUM s.r.o.
SEDIUM RD s.r.o.
SPUR a.s.
4P SYSTEM s.r.o.

Academical Workplaces

Charles University in Prague - Department of Medical Biochemistry

Charles University in Prague - Department of pharmacology and toxicology

Faculty Hospital in Hradec Kralove, Department of Metabolic Care and Gerontology

Brno University of Technology - Institute of physical and applied chemistry

Academy of Sciences of the Czech Republic, Laboratory of Free Radical Pathophysiology,

University of Pardubice - Department of Technology of Organic Compounds

nanomedic

Public funding of projects

This year CPN spol. s r.o. was awarded by first place in category Investition with the highest innovation potential.

Investor roku
Investor of the Year
2008

Contipro Group

Public funding of projects

Operational Programme Enterprise and Innovations (OPPI)

- Programme of support POTENTIAL (Project: R&D centre for medicinal nanobiotechnologies)
- Programme of support INNOVATION (Projects: Biotechnological manufacturing of polysaccharides and special peptides for applications in cosmetics, medicine and nanobiotechnologies; New applications of hyaluronan in pharmacy)
- Programme of support ICT IN ENTERPRISES (Projects: Improvement of decision making and communication processes i biotechnological company; Safe and effective distribution and data management in pharmaceutical company)
- Programme of support TRAINING CENTRES (Project: Training centre for pharmacy and nanotechnologies)
- Programme of support MARKETING (Projects: Propagation of company in the competitive environment; Expansion on novel markets)

Total costs on OPPI projects: 262 470 000 Kč, demand of funding: 131 235 000 Kč

Contipro Group

Public funding of projects

Operational Programme Enterprise and Innovations (OPPI)

Programme of support INNOVATION (Project: Manufacturing of hyaluronane by extraction and Hyiodine preparative – worldwide patent).

Operational Programme Education for competitiveness (Project: School of molecular biotechnology – Profession)

RESEARCH PROJECTS:

Tendering procedure MPO IMPULS (Project: Nanotechnologies in medicine –scaffold for reconstruction of connective tissue)

Tendering procedure MPO ENDURING PROSPERITY (Project: Biological active bandages)

Tendering procedure MPO TIP (Projects: New wound dressings based on nano- and micro- carriers; New hydrogels as materials for regenerative medicine and cosmetic dermatology)

Total costs on above listed projects: 177 766 000 Kč,
demand of funding: 64 157 000 Kč

Contipro Group

Thank you for your attention

www.contipro-group.cz